Molecular Generation for CNS Drug Discovery and Design

Area of Science:

• Computational chemistry
• Artificial intelligence in drug discovery
• Neuroscience

Background:

• Generative artificial intelligence (GenAI) is advancing drug design.
• Designing central nervous system (CNS) drugs faces challenges, including crossing the blood-brain barrier (BBB).
• The application of GenAI for CNS drug discovery is underexplored.

Purpose of the Study:

• To explore the potential of GenAI in designing CNS drugs.
• To highlight the importance of CNS drug-like properties and data resources.
• To advocate for specialized GenAI models tailored for CNS drug discovery.

Main Methods:

• Reviewing current GenAI techniques in drug design.
• Discussing CNS drug-like properties and relevant data sets.
• Proposing the integration of GenAI with experimental data and evaluation metrics.

Main Results:

• GenAI can be a powerful tool for exploring the CNS drug-like chemical space.
• Specialized GenAI models are needed to address BBB penetration and target engagement for CNS drugs.
• Integrating GenAI with experimental data can enhance CNS drug discovery efficiency.

Conclusions:

• GenAI holds significant promise for accelerating the discovery of novel CNS therapeutics.
• Developing targeted GenAI strategies is crucial for overcoming CNS drug design hurdles.
• Further research into specialized GenAI models can unlock new possibilities in treating neurological disorders.